Nonmetastatic castration-resistant prostate cancer

Area of Science:

• Oncology
• Urology

Background:

• Prostate cancer screening with PSA tests has shifted diagnosis to earlier stages.
• Local treatments (surgery, radiation) are common for early-stage disease.
• Androgen-deprivation therapy is used for treatment failure, potentially leading to castration-resistant prostate cancer (CRPC).

Purpose of the Study:

• To review the current understanding and management of nonmetastatic castration-resistant prostate cancer (NM-CRPC).
• To highlight the progression patterns and unmet needs in NM-CRPC.
• To discuss the limited therapeutic landscape for NM-CRPC.

Main Methods:

• Literature review of studies on prostate cancer screening, treatment, and progression.
• Analysis of clinical data regarding NM-CRPC patient outcomes.
• Evaluation of the efficacy of existing and investigational treatments for NM-CRPC.

Main Results:

• PSA screening has resulted in earlier prostate cancer diagnoses and increased local treatments.
• A significant proportion of patients progress to NM-CRPC, with about one-third developing bone metastasis within two years.
• Denosumab is the only agent shown to delay bone metastasis in NM-CRPC, without improving overall survival.

Conclusions:

• Physicians must recognize the heterogeneity of NM-CRPC.
• Current second-line treatments have primarily been studied in advanced metastatic CRPC.
• Further research is needed to establish effective treatments for NM-CRPC, focusing on delaying metastasis and improving survival.